New Managing Director at Aenova's Regensburg site

Dr Nancy Thiels has been appointed Managing Director of Haupt Pharma Amareg GmbH, the Regensburg site of Aenova, effective February 4, 2025. The experienced Managing Director will lead the site with more than 350 employees and focus on the development and production of highly effective solid oral dosage forms.

The Regensburg site is a competence center for the development, production and packaging of highly effective pharmaceutical products within the Aenova network, in particular anticancer and immunosuppressive drugs in solid oral dosage forms (tablets and capsules). Significant capacity expansions are planned at the Regensburg site over the next few years in close cooperation with customers. Dr Nancy Thiels has been responsible for business development at Aenova's Regensburg site since February 4, 2025. She replaces the long-time Managing Director Oliver Schmied, who is taking on new challenges.

Dr Nancy Thiels studied mechanical engineering at the Technical University of Kaiserslautern, Germany, where she also obtained her PhD. She has extensive experience in pharmaceutical production and process optimization in leading global companies, where she held various management positions for many years. "I am looking forward to my new role and the dedicated team in Regensburg. Every day, we develop and manufacture life-saving medicines for our customers, making an important contribution to the health of patients worldwide," explains Dr Nancy Thiels, Managing Director of Aenova’s Regensburg site. "At the same time, the focus is on continuous improvement, increasing efficiency and transforming the site as part of the Aenova Group's strategy."

"With Dr Nancy Thiels, we have gained an experienced expert who knows the industry inside out. Under her leadership, the Aenova site in Regensburg will continue to pursue its high standards of excellence and innovation," says Jan Kengelbach, CEO of the Aenova Group.